Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma.

Ranck MC, Golden DW, Corbin KS, Hasselle MD, Liauw SL, Stadler WM, Hahn OM, Weichselbaum RR, Salama JK.

Am J Clin Oncol. 2013 Dec;36(6):589-95. doi: 10.1097/COC.0b013e31825d52b2.

PMID:
22868242
2.

Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT).

Altoos B, Amini A, Yacoub M, Bourlon MT, Kessler EE, Flaig TW, Fisher CM, Kavanagh BD, Lam ET, Karam SD.

Radiat Oncol. 2015 Oct 28;10:218. doi: 10.1186/s13014-015-0528-z.

3.

Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control.

Stinauer MA, Kavanagh BD, Schefter TE, Gonzalez R, Flaig T, Lewis K, Robinson W, Chidel M, Glode M, Raben D.

Radiat Oncol. 2011 Apr 8;6:34. doi: 10.1186/1748-717X-6-34.

4.

Stereotactic body radiation therapy for curative treatment of adrenal metastases.

Rudra S, Malik R, Ranck MC, Farrey K, Golden DW, Hasselle MD, Weichselbaum RR, Salama JK.

Technol Cancer Res Treat. 2013 Jun;12(3):217-24. doi: 10.7785/tcrt.2012.500320. Epub 2013 Jan 25.

PMID:
23369155
5.

A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma.

Svedman C, Sandström P, Pisa P, Blomgren H, Lax I, Kälkner KM, Nilsson S, Wersäll P.

Acta Oncol. 2006;45(7):870-5.

PMID:
16982552
6.

Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma.

Ponsky L, Lo SS, Zhang Y, Schluchter M, Liu Y, Patel R, Abouassaly R, Welford S, Gulani V, Haaga JR, Machtay M, Ellis RJ.

Radiother Oncol. 2015 Oct;117(1):183-7. doi: 10.1016/j.radonc.2015.08.030. Epub 2015 Sep 8.

PMID:
26362723
7.

Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy.

Nguyen QN, Shiu AS, Rhines LD, Wang H, Allen PK, Wang XS, Chang EL.

Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1185-92. doi: 10.1016/j.ijrobp.2009.03.062. Epub 2009 Jul 23.

PMID:
19632064
8.

Spine stereotactic body radiotherapy for renal cell cancer spinal metastases: analysis of outcomes and risk of vertebral compression fracture.

Thibault I, Al-Omair A, Masucci GL, Masson-Côté L, Lochray F, Korol R, Cheng L, Xu W, Yee A, Fehlings MG, Bjarnason GA, Sahgal A.

J Neurosurg Spine. 2014 Nov;21(5):711-8. doi: 10.3171/2014.7.SPINE13895. Epub 2014 Aug 29.

PMID:
25170656
9.

Single-fraction stereotactic body radiotherapy for spinal metastases from renal cell carcinoma.

Balagamwala EH, Angelov L, Koyfman SA, Suh JH, Reddy CA, Djemil T, Hunter GK, Xia P, Chao ST.

J Neurosurg Spine. 2012 Dec;17(6):556-64. doi: 10.3171/2012.8.SPINE12303. Epub 2012 Sep 28.

PMID:
23020208
10.

A dose-response relationship for time to bone pain resolution after stereotactic body radiotherapy (SBRT) for renal cell carcinoma (RCC) bony metastases.

Jhaveri PM, Teh BS, Paulino AC, Blanco AI, Lo SS, Butler EB, Amato RJ.

Acta Oncol. 2012 May;51(5):584-8. doi: 10.3109/0284186X.2011.652741. Epub 2012 Jan 17.

PMID:
22248089
11.

Clinical outcome of stereotactic radiosurgery for central nervous system metastases from renal cell carcinoma.

Seastone DJ, Elson P, Garcia JA, Chao ST, Suh JH, Angelov L, Rini BI.

Clin Genitourin Cancer. 2014 Apr;12(2):111-6. doi: 10.1016/j.clgc.2013.10.001. Epub 2013 Oct 22.

PMID:
24331575
12.

Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant?

Amini A, Altoos B, Bourlon MT, Bedrick E, Bhatia S, Kessler ER, Flaig TW, Fisher CM, Kavanagh BD, Lam ET, Karam SD.

Pract Radiat Oncol. 2015 Nov-Dec;5(6):e589-e596. doi: 10.1016/j.prro.2015.05.004. Epub 2015 Jun 30.

13.

Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney.

Svedman C, Karlsson K, Rutkowska E, Sandström P, Blomgren H, Lax I, Wersäll P.

Acta Oncol. 2008;47(8):1578-83. doi: 10.1080/02841860802123196.

PMID:
18607859
14.

Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies.

Goodman KA, Wiegner EA, Maturen KE, Zhang Z, Mo Q, Yang G, Gibbs IC, Fisher GA, Koong AC.

Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):486-93. doi: 10.1016/j.ijrobp.2009.08.020. Epub 2010 Mar 28.

PMID:
20350791
15.

Clinical outcomes and dosimetric considerations using stereotactic body radiotherapy for abdominopelvic tumors.

Barney BM, Olivier KR, Macdonald OK, Fong de Los Santos LE, Miller RC, Haddock MG.

Am J Clin Oncol. 2012 Dec;35(6):537-42. doi: 10.1097/COC.0b013e31821f876a.

PMID:
21659830
16.

Gamma knife radiosurgery for brainstem metastases: the UCSF experience.

Kased N, Huang K, Nakamura JL, Sahgal A, Larson DA, McDermott MW, Sneed PK.

J Neurooncol. 2008 Jan;86(2):195-205. Epub 2007 Jul 13.

PMID:
17628747
17.

Single-fraction versus multifraction spinal stereotactic radiosurgery for spinal metastases from renal cell carcinoma: secondary analysis of Phase I/II trials.

Ghia AJ, Chang EL, Bishop AJ, Pan HY, Boehling NS, Amini B, Allen PK, Li J, Rhines LD, Tannir NM, Tatsui CE, Brown PD, Yang JN.

J Neurosurg Spine. 2016 May;24(5):829-36. doi: 10.3171/2015.8.SPINE15844. Epub 2016 Jan 22.

PMID:
26799117
18.

Adjuvant stereotactic body radiotherapy for resected pancreatic adenocarcinoma with close or positive margins.

Rwigema JC, Heron DE, Parikh SD, Zeh HJ 3rd, Moser JA, Bahary N, Ashby K, Burton SA.

J Gastrointest Cancer. 2012 Mar;43(1):70-6. doi: 10.1007/s12029-010-9203-7.

PMID:
20809393
19.

A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases.

Fumagalli I, Bibault JE, Dewas S, Kramar A, Mirabel X, Prevost B, Lacornerie T, Jerraya H, Lartigau E.

Radiat Oncol. 2012 Sep 27;7:164. doi: 10.1186/1748-717X-7-164.

20.

Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.

Wang CJ, Christie A, Lin MH, Jung M, Weix D, Huelsmann L, Kuhn K, Meyer J, Desai N, Kim DWN, Pedrosa I, Margulis V, Cadeddu J, Sagalowsky A, Gahan J, Laine A, Xie XJ, Choy H, Brugarolas J, Timmerman R, Hannan R.

Int J Radiat Oncol Biol Phys. 2017 May 1;98(1):91-100. doi: 10.1016/j.ijrobp.2017.01.032.

Supplemental Content

Support Center